118.92

0.71% 0.6208

Gilead Sciences Inc (GILD)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché GILD Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Precedente Chiudi:

$118.30

Aprire:

$117.98

Volume 24 ore:

2.48M

Relative Volume:

0.38

Capitalizzazione di mercato:

$147.48B

Reddito:

$28.80B

Utile/perdita netta:

$6.31B

Rapporto P/E:

23.66

EPS:

5.0273

Flusso di cassa netto:

$9.37B

1 W Prestazione:

+2.05%

1M Prestazione:

+7.47%

6M Prestazione:

+13.59%

1 anno Prestazione:

+37.33%

Intervallo 1D:

$117.98

$121.57

Intervallo di 1 settimana:

$115.80

$121.57

Portata 52W:

$85.60

$121.83

Gilead Sciences Inc Stock (GILD) Company Profile

Nome

Gilead Sciences Inc

Settore

Healthcare (1143)

Industria

Drug Manufacturers - General (19)

Telefono

(650) 574-3000

Indirizzo

333 LAKESIDE DR, FOSTER CITY, CA

Dipendente

17,600

Cinguettio

@GileadSciences

Prossima data di guadagno

2025-02-11

Ultimi documenti SEC

GILD's Discussions on Twitter

Confronta GILD con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
GILD Gilead Sciences Inc	118.86	147.01B	28.80B	6.31B	9.37B	5.0273
LLY Lilly Eli Co	820.57	728.24B	53.26B	13.80B	-50.20M	15.08
JNJ Johnson Johnson	191.76	459.63B	92.15B	25.12B	18.18B	10.36
ABBV Abbvie Inc	226.79	404.77B	58.33B	3.73B	18.24B	2.1013
NVS Novartis Ag Adr	130.74	252.16B	53.40B	13.68B	16.89B	6.8864
MRK Merck Co Inc	84.12	211.56B	63.43B	16.42B	14.72B	6.4861

Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-08-19	Aggiornamento	Daiwa Securities	Neutral → Outperform
2025-08-08	Aggiornamento	Truist	Hold → Buy
2025-07-25	Aggiornamento	Needham	Hold → Buy
2025-04-22	Ripresa	Cantor Fitzgerald	Overweight
2025-03-04	Reiterato	Oppenheimer	Outperform
2025-02-18	Aggiornamento	Deutsche Bank	Hold → Buy
2025-02-13	Aggiornamento	DZ Bank	Hold → Buy
2025-01-10	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2024-12-10	Ripresa	BofA Securities	Buy
2024-11-15	Iniziato	Wolfe Research	Outperform
2024-11-14	Iniziato	Citigroup	Buy
2024-11-08	Downgrade	Maxim Group	Buy → Hold
2024-10-21	Aggiornamento	Leerink Partners	Market Perform → Outperform
2024-10-17	Iniziato	Bernstein	Outperform
2024-10-07	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2024-07-08	Aggiornamento	Raymond James	Mkt Perform → Outperform
2024-05-01	Reiterato	Maxim Group	Buy
2024-04-24	Aggiornamento	HSBC Securities	Reduce → Hold
2024-02-22	Downgrade	Truist	Buy → Hold
2023-11-09	Iniziato	Deutsche Bank	Hold
2023-09-08	Aggiornamento	BofA Securities	Neutral → Buy
2023-09-06	Iniziato	HSBC Securities	Reduce
2023-07-24	Reiterato	Barclays	Equal Weight
2023-05-16	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2023-04-28	Ripresa	Piper Sandler	Overweight
2023-01-03	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2022-12-13	Ripresa	BofA Securities	Neutral
2022-12-09	Downgrade	DZ Bank	Buy → Hold
2022-10-31	Aggiornamento	Barclays	Underweight → Equal Weight
2022-10-28	Reiterato	BMO Capital Markets	Market Perform
2022-10-28	Reiterato	Cowen	Outperform
2022-10-28	Reiterato	JP Morgan	Overweight
2022-10-28	Reiterato	Jefferies	Buy
2022-10-28	Aggiornamento	Piper Sandler	Neutral → Overweight
2022-10-28	Reiterato	RBC Capital Mkts	Outperform
2022-10-28	Aggiornamento	Truist	Hold → Buy
2022-10-28	Reiterato	Wells Fargo	Equal Weight
2022-10-04	Aggiornamento	JP Morgan	Neutral → Overweight
2022-07-13	Iniziato	Cantor Fitzgerald	Neutral
2022-05-23	Iniziato	SVB Leerink	Mkt Perform
2022-02-28	Downgrade	BMO Capital Markets	Outperform → Market Perform
2022-02-02	Reiterato	BMO Capital Markets	Outperform
2022-02-02	Reiterato	BofA Securities	Neutral
2022-02-02	Reiterato	RBC Capital Mkts	Outperform
2022-02-02	Reiterato	Truist	Hold
2022-02-02	Reiterato	Wells Fargo	Equal Weight
2022-01-28	Aggiornamento	Argus	Hold → Buy
2022-01-06	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2021-12-09	Ripresa	Wells Fargo	Equal Weight
2021-12-06	Iniziato	Goldman	Neutral
2021-11-19	Aggiornamento	BMO Capital Markets	Market Perform → Outperform
2021-11-19	Ripresa	Piper Sandler	Neutral
2021-10-20	Ripresa	Cowen	Outperform
2021-07-30	Reiterato	BMO Capital Markets	Market Perform
2021-07-30	Reiterato	RBC Capital Mkts	Outperform
2021-04-01	Aggiornamento	Bernstein	Mkt Perform → Outperform
2021-03-30	Aggiornamento	Redburn	Neutral → Buy
2021-01-19	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2021-01-04	Aggiornamento	Guggenheim	Neutral → Buy
2020-11-03	Ripresa	Morgan Stanley	Equal-Weight
2020-10-28	Iniziato	UBS	Neutral
2020-09-30	Ripresa	Jefferies	Buy
2020-09-15	Aggiornamento	Maxim Group	Hold → Buy
2020-07-31	Reiterato	Credit Suisse	Neutral
2020-07-31	Reiterato	Morgan Stanley	Equal-Weight
2020-07-31	Reiterato	Piper Sandler	Overweight
2020-07-31	Reiterato	RBC Capital Mkts	Outperform
2020-07-31	Reiterato	SunTrust	Hold
2020-07-31	Reiterato	Wells Fargo	Equal Weight
2020-07-20	Aggiornamento	Credit Suisse	Underperform → Neutral
2020-06-03	Aggiornamento	SVB Leerink	Mkt Perform → Outperform
2020-05-26	Aggiornamento	SunTrust	Sell → Hold
2020-05-01	Downgrade	JP Morgan	Overweight → Neutral
2020-05-01	Downgrade	Raymond James	Outperform → Mkt Perform
2020-05-01	Downgrade	SunTrust	Hold → Sell
2020-04-27	Downgrade	UBS	Buy → Neutral
2020-04-20	Downgrade	BMO Capital Markets	Outperform → Market Perform
2020-04-20	Downgrade	Wells Fargo	Overweight → Equal Weight
2020-04-17	Downgrade	CFRA	Hold → Sell

Mostra tutto

Gilead Sciences Inc Borsa (GILD) Ultime notizie

Oct 15, 2025

Gilead presents new HIV research data at EACS 2025 – driving scientific innovation in treatment and prevention - European AIDS Treatment Group

Oct 15, 2025

Gilead to present data on potential first weekly oral treatment for HIV - Clinical Trials Arena

Oct 15, 2025

Merck's New HIV Treatment Works As Well As Top Drug In Late Trials - Benzinga

Oct 15, 2025

Gilead highlights HIV pipeline at European AIDS Conference - The Pharma Letter

Oct 15, 2025

Sjogren’s Syndrome Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | Gilead Sciences, Incyte Corp, Novartis, GlaxoSmithKline, Janssen Research & Development, LLC - Barchart.com

Oct 15, 2025

ViiV says its HIV PrEP therapy outperformed Gilead’s lenacapavir in early-stage trial - Seeking Alpha

Oct 15, 2025

Gilead Presents New HIV Research Data at EACS 2025 – Driving Scientific Innovation in Treatment and Prevention - BioSpace

Oct 15, 2025

Gilead (GILD) Showcases Advances in HIV Research at European AIDS Conference - GuruFocus

Oct 15, 2025

Gilead presents new HIV research data at European AIDS Conference - StreetInsider

Oct 15, 2025

Oct 14, 2025

Chinese Research Org. Says Gilead Infringed COVID Patent - Law360

Oct 14, 2025

Gilead and Arcus see survival boost with gastric cancer combo - The Pharma Letter

Oct 14, 2025

Oct 13, 2025

Gilead Sciences/Arcus Biosciences' Investigational Cancer Drug Shows Overall Survival Of Around 27 Months - Benzinga

Oct 13, 2025

Gilead to present promising data for Trodelvy in breast cancer at ESMO - Investing.com

Oct 13, 2025

Gilead to present Trodelvy breast cancer data at ESMO 2025 - StreetInsider

Oct 13, 2025

Gilead, Coinbase, Rocket Lab And A Tech Stock On CNBC's 'Final Trades' - Benzinga

Oct 13, 2025

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025 - Business Wire

Oct 13, 2025

Yousif Capital Management LLC Sells 2,855 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 13, 2025

Survival data boost prospects for Gilead, Arcus TIGIT drug in gastric cancer - firstwordpharma.com

Oct 13, 2025

ADAPT: Accelerating Disability Awareness & Progress Together - Gilead Sciences

Oct 13, 2025

Oct 12, 2025

OFI Invest Asset Management Sells 86,817 Shares of Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025

Transcendent Capital Group LLC Invests $432,000 in Gilead Sciences, Inc. $GILD - MarketBeat

Oct 12, 2025